New update about CYP2D6

hlya
hlya Member Posts: 484
edited June 2014 in ILC (Invasive Lobular Carcinoma)

I posted in another forum but would like to share with you ILC girls here again:

http://community.breastcancer.org/forum/78/topic/747562?page=1#idx_15

"A new study that found "slow metabolizers" of tamoxifen did not have a higher risk of recurrence has spurred further controversy over whether patients who don't fully metabolize the drug get the full benefit. The analysis, presented Friday at the San Antonio Breast Cancer Symposium, included more than 2,800 women with early-stage, estrogen receptor-positive breast cancer who received tamoxifen after surgery....

....."

http://www.curetoday.com/index.cfm/fuseaction/article.show/id/2/article_id/1338

· Share on FacebookShare on Twitter

Comments

  • AnnNYC
    AnnNYC Member Posts: 4,484
    edited January 2010

    In the same article, it also says:

    "Recent studies looking at the interaction between tamoxifen and CYP2D6 have been contradictory. Indeed, a study presented at last year's meeting reported that in patients treated with tamoxifen, those who were slow metabolizers had a nearly four-fold higher chance of early recurrence compared with high metabolizers. Data from large prospective trials-a study design that looks forward in time as opposed to backward-are needed to clarify whether an association really exists."

    · Share on FacebookShare on Twitter

Categories